Viridian Therapeutics raises $350M in upsized dual public offerings
What's the deal? Viridian Therapeutics, a biotech company focused on autoimmune and rare diseases, has priced two concurrent public offerings totalling $350M in gross proceeds. The Waltham, Massachusetts-based company is issuing $225M in convertible senior notes due 2032 and selling roughly 7.4 million shares of common stock at $17.00 per share.
After underwriting discounts and expenses, Viridian expects net proceeds of approximately $334.7M. Both offerings were upsized from their original size.
The convertible notes carry a 1.75% interest rate and mature on May 15, 2032. Noteholders can convert at an initial price of roughly $24.65 per share — a 45% premium over the equity offering price. Both offerings are expected to close on May 11, 2026.
Viridian has also granted underwriters 30-day options to purchase up to an additional $25M in convertible notes and about 1.1 million extra shares to cover over-allotments.
Why now? Biotech companies often tap capital markets when they need to fund late-stage clinical programmes or prepare for commercialisation. Running two offerings simultaneously — debt and equity — lets Viridian diversify its funding sources while the convertible note market remains receptive to life sciences issuers.
The dual structure also signals confidence from underwriters willing to upsize both tranches, suggesting strong investor demand.
What could go wrong? Issuing convertible notes and new shares at the same time creates dilution risk for existing shareholders. If Viridian's stock stays below the $24.65 conversion price, the notes become straight debt that still accrues interest — adding to the company's obligations without the upside of equity conversion.
Biotech is inherently risky. If clinical trials disappoint or regulatory approvals stall, servicing $225M in debt on top of operational cash burn could strain the balance sheet.
The signal: Viridian's upsized raise reflects a broader trend of mid-cap biotechs using creative capital structures to extend their runways. Convertible notes have become a favoured tool in the sector — they offer lower interest rates than traditional debt while giving investors equity upside.
The fact that both offerings were upsized suggests the appetite for autoimmune and rare disease assets remains strong, even in a volatile market for biotech equities.
Read more: viridiantherapeutics.com
